500 patients67,039 observations150 daysLIVE

Patient P-03090

Synthetic patientONX-7 · Day 147 · 55–64 · F · baseline S02Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Declining
Discontinuation risk
68%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S02
  2. Day 62 GI-04 recommendedGI Support Protocol GI-04
  3. Day 63 Patient acceptedStarted GI-04 in the companion
  4. Day 71 GI symptom burden −40% vs expectedGI Support Protocol GI-04
  5. Day 75 Trajectory diverged from predictionObserved response fell below the model's expected path.
  6. Day 75 ME-01 recommendedMonitoring Escalation ME-01
  7. Day 76 Patient acceptedStarted ME-01 in the companion
  8. Day 77 Tolerance state changedUnstable → Improving
  9. Day 79 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 75.

Primary contributors, last 14 days
  • Nutritional resilience-15
  • GI instability+12
  • Treatment adherence+8

What helped?

  • GI Support Protocol GI-04Day 62
    Result: symptom burden −40%
  • Monitoring Escalation ME-01Day 75
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
60%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 73% showed improvement
  • median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
4.5/10
stable · +0.1 vs previous 14 d
Stress level
Daily log
5.6/10
stable · -0.1 vs previous 14 d
Pessimism score
Daily log
5.7/10
stable · -0.1 vs previous 14 d
Sleep quality
Wearable
46.2/100
worsening · -4.8 vs previous 14 d
Libido
Daily log
3.9/10
stable · -0.1 vs previous 14 d
HRV
Wearable
39.6 ms
worsening · -2.2 vs previous 14 d
Toxicity
Blood
37.8/100
improving · -2.7 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 36 from the failing basin, 52 from restoration.

Would help
  • DT-01 Dosing / Timing Recommendation
    73% improved among 11 similar · onset 5 d · confidence 66%
  • NP-02 Dietary Support Protocol
    57% improved among 14 similar · onset 10 d · confidence 66%
  • CR-01 Clinician Review
    100% improved among 5 similar · onset 5 d · confidence 66%
  • More protein
    GI -4 next day on high-intake days · n 18
Would not help
  • AD-05 Adherence Support
    only 30% improved among 10 similar
  • Keep fat low
    GI +4.6 next day on high-intake days · n 22
  • Keep histamine low
    GI +4.6 next day on high-intake days · n 26
  • Keep lactose low
    GI +3.3 next day on high-intake days · n 14
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +4.6detractor · 95%
  • Histamine load
    +4.6detractor · 95%
  • Protein
    -4supporter · 95%
  • Lactose
    +3.3detractor · 77%
  • Caffeine
    +2no signal · 37%
  • Alcohol
    +0.6no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 53 and rising
  • Inflammatory signalling 70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 47
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 28/100
    • Daily logFibre intake low in recent food logs
  • Autonomic recovery 20
    • Wearable3,504 steps/day
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Rapid metabolizer
    Expected exposure
Microbiome
Shannon diversity 3 · butyrate capacity 28/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
46 ms
Sleep
6.8 h
Steps
3,732
Resting HR
69 bpm
Daily log: GI score 53, nutritional resilience 43, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0338235%S01GI-04improved56
P-0338433%S0155
P-0307426%S0160
P-0338925%S0150
P-0344325%S0152
P-0301424%S0132
P-0317724%S0128
P-0325524%S01HY-01improved53
P-0338124%S0155
P-0309223%S0161
P-0305322%S0139
P-0312822%S0132